Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give Insulet a consensus recommendation of Moderate Buy from 24 firms (18 buys, 5 holds, 1 sell) with an average 12‑month price target of $327.24.
• Insulet beat Q1 expectations with EPS of $1.55 versus $1.48 expected and revenue of $783.8M (+31.2% YoY); the company has a $12.12B market cap and a P/E of 50.01.
• A company director purchased 2,030 shares (~$499,847) in late February, increasing ownership ~13%, even as several major brokers (JPMorgan, Stifel, BTIG, Truist) have recently trimmed their price targets.

Shares of Insulet Corporation (NASDAQ:PODD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-four ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $327.2381.

A number of analysts have issued reports on PODD shares. Royal Bank Of Canada reissued an "outperform" rating and issued a $325.00 target price on shares of Insulet in a research report on Tuesday, April 14th. Stifel Nicolaus decreased their target price on Insulet from $370.00 to $350.00 and set a "buy" rating for the company in a research report on Wednesday, February 4th. JPMorgan Chase & Co. decreased their target price on Insulet from $415.00 to $340.00 and set an "overweight" rating for the company in a research report on Thursday, February 19th. BTIG Research decreased their target price on Insulet from $380.00 to $320.00 and set a "buy" rating for the company in a research report on Monday, April 13th. Finally, Truist Financial decreased their target price on Insulet from $360.00 to $315.00 and set a "buy" rating for the company in a research report on Wednesday, April 15th.

Insulet Stock Performance

NASDAQ:PODD opened at $175.04 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The business has a fifty day simple moving average of $216.37 and a two-hundred day simple moving average of $267.50. Insulet has a 1 year low of $158.35 and a 1 year high of $354.88. The company has a market capitalization of $12.12 billion, a P/E ratio of 50.01, a P/E/G ratio of 1.05 and a beta of 1.20.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same period last year, the business posted $1.15 earnings per share. The business's revenue for the quarter was up 31.2% on a year-over-year basis. On average, analysts expect that Insulet will post 6.27 earnings per share for the current year.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.36% of the company's stock.

Hedge Funds Weigh In On Insulet

Hedge funds have recently made changes to their positions in the stock. Winnow Wealth LLC purchased a new position in shares of Insulet in the third quarter valued at $862,000. Nordea Investment Management AB grew its position in shares of Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier's stock valued at $157,128,000 after purchasing an additional 142,922 shares in the last quarter. Machina Capital S.A.S. purchased a new position in shares of Insulet in the third quarter valued at $2,778,000. Jain Global LLC grew its position in shares of Insulet by 148.2% in the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier's stock valued at $32,945,000 after purchasing an additional 63,719 shares in the last quarter. Finally, ING Groep NV grew its position in shares of Insulet by 88.5% in the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier's stock valued at $5,341,000 after purchasing an additional 8,123 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.